Health
News Scan for Apr 19, 2021 – CIDRAP
CARB-X to fund development of bacteriophage-based drug
CARB-X announced today that it is awarding Phico Therapeutics of Cambridge, United Kingdom, up to $5.3 million to develop an intravenous bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
The award will support development of Phico’s SASPject PT 3.9 project, which combines engineered bacteriophages with antibacterial small acid-soluble spore proteins (SASPs) to target and inactivate P aeruginosa bacteria….
-
General14 hours ago‘We are here for you’: PM to bring help to flood zones
-
General13 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News21 hours agoStudents say new facility would be better in rural areas of Queensland
-
General8 hours agoInternal Revenue Service starts cutting 20,000 workers